Wedbush Reiterates Neutral on Kinnate Biopharma, Maintains $2 Price Target
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten has reiterated a Neutral rating on Kinnate Biopharma (NASDAQ:KNTE) and maintained a price target of $2.
January 17, 2024 | 1:32 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Wedbush analyst reaffirms Neutral rating on Kinnate Biopharma with a $2 price target, indicating no significant change in the stock's outlook.
The reiteration of a Neutral rating and maintenance of the price target suggests that there are no new significant developments expected to impact Kinnate Biopharma's stock price in the short term. The analyst's view remains unchanged, indicating a stable outlook for the stock.
CONFIDENCE 90
IMPORTANCE 50
RELEVANCE 100